Paramita Chakraborty
Research Assistant Professor
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (21)
The cGAS-STING pathway plays a central role in controlling tumor progression through nucleic acid sensing and type I Interferon production. Here, we identify Poly(rC) Binding Protein 1 as a tumor suppressor that amplifies cGAS-STING signaling in breast cancer. Using patient datasets and a transgenic mouse model with conditional PCBP1 knockout in mammary epithelial cells, we show that PCBP1 expression correlates with improved survival, reduced tumor burden, increased type I Interferon and Interferon Stimulated Gene expression, and elevated cytotoxic T cell infiltration. Mechanistically, PCBP1 binds cytosine-rich single-stranded motifs via its KH domains and increases cGAS affinity to these nucleic acids. Mutation of PCBP1’s conserved GXXG loops impairs nucleic acid binding and cGAS activation. Although cGAS is a double-stranded DNA sensor with no intrinsic sequence specificity, we uncover that the single-stranded nucleic-acid binding protein PCBP1 enhances cGAS sensing by engaging sequence-specific motifs, acting as a nucleic acid co-sensor that impairs tumorigenesis.
Year:
2026
Year:
2026
Patients with Alzheimer's disease (AD) have a decreased incidence of cancer, with a cross-sectional analysis of a nationwide sample of adults finding 21-fold higher odds of cancer diagnosis in non-AD individuals compared with those with AD. In this study, we demonstrated that mitochondrial localization of AD-associated amyloid-β precursor protein (APP) and its cleavage product amyloid-β 40, but not mutant APP that lacks a mitochondrial localization signal, inhibits lipid stress–mediated hyperactive mitophagy in aging T cells, improving their antitumor functions. Growth of melanoma xenograft or carcinogen-induced oral cancer models was highly reduced in AD mice. Additionally, adoptive cell transfer–based immunotherapy using aging T cells isolated from AD mice suppressed tumor growth. The metabolic signature of stress-dependent mitophagy in T cells showed fumarate depletion, which was linked to decreased succination of Parkin and enhanced mitochondrial damage. Mechanistically, APP interaction with the TOMM complex at the outer mitochondrial membrane attenuated trafficking of ceramide synthase CerS6 to mitochondria in aging AD T cells, preventing ceramide-dependent mitophagy. Thus, APP restored mitochondrial fumarate metabolism and Parkin succination, improving antitumor functions of AD T cells in vitro and in vivo. Exogenous fumarate supplementation or healthy AD mitochondria transfer functionally mimicked the AD/APP phenotype in aging T cells, enhancing their antitumor activity to control tumor growth. Moreover, T cells isolated from aging donors showed elevated mitophagy with fumarate depletion, which was restored in T cells isolated from age-matched patients with AD. Together, these findings show that AD protects T cells against ceramide-dependent mitophagy and fumarate depletion to enhance antitumor functions. Significance: The reduced cancer risk in Alzheimer's disease patients is mediated by the amyloid-β 40 peptide, which inhibits aging-dependent mitophagy in T cells to improve antitumor immunity. See related commentary by Bieberich, p. 3579
Year:
2025
Background: Ovarian cancer remains the most lethal gynecologic malignancy and a leading cause of cancer-related deaths among women. Adoptive cell therapy (ACT) using tumor-infiltrating lymphocytes (TILs) has shown success in melanoma and correlates with survival in ovarian cancer. However, its application remains limited, partly due to inefficient expansion of functional, tumor-specific T cells. Methods: We developed a novel ex vivo expansion platform for ovarian TILs, integrating metabolic and phenotypic reprogramming with selective enrichment for tumor-reactive populations. Tissue from nine patients with stage III/IV high-grade epithelial ovarian carcinoma was collected for banking, NGS, and TIL expansion. Four had matched TILs expanded pre- and post-neoadjuvant chemotherapy. The initial priming phase employed our published cytokine cocktail designed to induce Th1/17 and Th17/Tc17 polarization, to promote effector differentiation while preserving stemness. TILs were cultured for five days in this cocktail to enhance metabolic fitness and anti-tumor potential. CD137+ (4-1BB+) T cells were isolated based on activation-induced co-stimulatory expression and subjected to rapid expansion using a G-Rex-based bioreactor system with irradiated feeder cells, anti-CD3, and low-dose IL-2. Expanded TILs were characterized by multicolor flow cytometry, CD107a degranulation, IFN-γ ELISA, and single-cell RNA sequencing (scRNA-seq), and benchmarked against TILs expanded using the conventional protocol from NCI. Results: Our approach reliably produced 15–20 billion viable TILs per patient within 30 days, achieving >95% viability and ∼2500-fold expansion. CD137+ enrichment enhanced tumor reactivity, as shown by increased IFN-γ secretion and degranulation with autologous tumor and high-grade serous ovarian cancer cell lines. scRNA-seq revealed enriched cytotoxic CD8+ T cells and mucosal-associated invariant T (MAIT) cells, with reduced FOXP3+ regulatory and non-cytotoxic CD4+ subsets, compared to TILs from matched blood, tumor, and those expanded with high-dose IL-2 in the NCI protocol. CD8+ proliferative and cytotoxic T cell subsets were enriched under the hybrid CD137-sorted protocol. Transcriptomic profiling showed that CD8+ proliferating T cells from the hybrid group downregulated key metabolic genes, including SLC7A5 and LDHB, suggesting a rewired metabolic state that may support persistence. Similarly, CD8+ cytotoxic T cells showed chromatin remodeling, with upregulation of histone demethylases KDM5A and KDM7A, and downregulation of CHD7 and JARID2, indicating transcriptional plasticity. MAIT cells also showed increased activation markers (IFNG, CCL20). Expanded TILs exhibited reduced expression of exhaustion markers PD-1 and CD38 at the protein level. Conclusion: Metabolic reprogramming combined with CD137-based enrichment enables robust expansion of metabolically reprogrammed, tumor-specific TILs from ovarian tumors. This strategy offers a promising foundation for advancing TIL-based ACT in ovarian cancer. Citation Format: Paramita Chakraborty, Stephanie Mills, Jadan Zavestoski, Satyajit Das, Suganya Subramanian, Nicolina Mascia, Jian Liu, Stefano Berto, Brian Orr, Shikhar Mehrotra, Stephanie Mills. Metabolic reprogramming of ovarian CD137+ TILs for treatment [abstract]. In: Proceedings of the AACR Special Conference in Cancer Research: Advances in Ovarian Cancer Research; 2025 Sep 19-21; Denver, CO. Philadelphia (PA): AACR; Cancer Res 2025;85(18_Suppl):Abstract nr PR006.
Year:
2025
Description Tumor-Infiltrating Lymphocytes (TILs) Immunotherapy uses multiple strategies to expand tumor-specific T cells ex-vivo. Effective expansion is crucial to enhance therapeutic efficacy. Traditional manufacturing processes are time-consuming and require high doses of IL-2, which can compromise quality and functionality of TILs. We aimed to improve TIL expansion across various solid tumors, including prostate cancer, where previous methods fail from poor immunogenicity. TILs were isolated from human prostate, melanoma, ovarian and lung tumor biopsies, and were programmed in a preformulated cytokine mixture for 6 days prior to rapid expansion using a G-REX system. The expansion process was monitored by flow cytometry. Additionally, TILs were re-stimulated or co-cultured with tumor cell lines and functionality was assessed by cytokine release. Our 30-day protocol expanded 0.4-1.5 million TILs from human tumor tissue to around 8-10 billion functional TILs, achieving greater than 2000-fold expansion. Expanded TILs retained over 95% viability and robust production of IFNγ upon re-stimulation, indicating the preservation of functional potency. Our 30-day expansion protocol successfully generates large quantities of highly functional TILs from multiple different tumors including characteristically ‘cold’ solid tumors. This approach holds significant promise for enhancing the efficacy of TIL-based immunotherapies and offers a scalable solution for clinical applications. Funding Sources NIH 5TL1 TR001451, NIH 2R42CA239952. MUSC Translational Science Lab, MUSC Flow Cytometry Core Topic Categories Tumor Immunology: Checkpoints, Prevention, and Treatment (TIPT)
Year:
2025
Description Immunosuppressive myeloid populations, like myeloid-derived suppressor cells (MDSCs), within the tumor microenvironment (TME), hinder cancer immunotherapy. Targeting this suppression is vital to enhance anti-tumor T cell function in the TME. Our research shows that inhibiting SphK2-mediated S1P generation in MDSCs reshapes the TME, promoting tumor control. In preclinical checkpoint-resistant breast, bladder, and melanoma cancer models, SphK2 inhibition sensitizes tumors to anti-PD1 therapy, reducing tumor growth by alleviating MDSC suppression. Mechanistically, the MS-based proteomics analysis revealed that S1P interacts with Acetyl CoA carboxylase isoforms (ACC1 and ACC2), key enzymes in fatty acid metabolism. Enhancing ACC1/2 activity reprograms MDSC metabolism by increasing glycolysis through elevated Pyruvate Kinase M2 activity while reducing fatty acid oxidation. This metabolic shift promotes an immunogenic MDSC phenotype, enhancing antigen presentation to T cells. Moreover, lipidomic analysis showed that altered ACC1/2 activity increases fatty acid synthesis, particularly phosphatidylcholine (PC). Notably, PC supplementation alleviates ER stress in tumor-associated MDSCs, a key driver of their suppressive function. These findings establish S1P as a critical immunoregulatory mediator and PC as an immunostimulatory molecule, highlighting the SphK2/ACC/phospholipid axis as a promising target to counteract immunosuppression and enhance the efficacy of cancer immunotherapy. Funding Sources Department of Surgery, MUSC, Swim Across America foundation (SAA) NCI R01 CA250458, R01 CA236379 Topic Categories Tumor Immunology: Cellular Responses and Tumor Microevironment (TIME)
Year:
2025
Description The bioactive lysophospholipid sphingosine-1-phosphate (S1P) is critical for lymphocyte trafficking and functions via the S1P-S1PR1 axis, but the impact of intracellular S1P levels on CD4+ T cell functions remain unclear. This study investigates the S1P transporter SPNS2 in regulating cytotoxic CD4+ T cells through S1P accumulation. CD4+ T cells from SPNS2 knockout (KO) mice exhibited an increased effector population with a cytotoxic phenotype, marked by elevated immune receptor activity and cytokine expression. Polarization toward the Th1 phenotype was significantly enhanced, as shown by increased T-bet and IFN-γ expression, an effect further amplified by SPNS2 inhibition (SLF1081851). SPNS2 KO CD4+ T cells displayed significantly elevated mitochondrial oxygen consumption rates (OCR), reflecting increased oxidative phosphorylation (OXPHOS), and RNA-seq analysis revealed upregulation of lipid metabolism pathways, aligning with their heightened functionality. In the B16-F10 melanoma model, SPNS2 KO mice demonstrated delayed tumor progression and improved survival. Tumor-infiltrating lymphocytes (TILs) from KO mice showed elevated activation markers and proinflammatory cytokines (IFN-γ, TNF-α), underscoring enhanced anti-tumor activity. These findings suggest that targeting SPNS2-mediated S1P metabolism in CD4+ T cells offers a promising strategy for cancer immunotherapy. Funding Sources Supported by NIH R01 CA250458; R01 CA236379; RO1 DE030013; R41 CA271958; R01CA282408-01A1; 2R42CA239952-02 Topic Categories Tumor Immunology: Cellular Responses and Tumor Microevironment (TIME)
Year:
2025
Year:
2025
Patients with Alzheimer's disease (AD) have a decreased incidence of cancer, with a cross-sectional analysis of a nationwide sample of adults finding 21-fold higher odds of cancer diagnosis in non-AD individuals compared with those with AD. In this study, we demonstrated that mitochondrial localization of AD-associated amyloid-β precursor protein (APP) and its cleavage product amyloid-β 40, but not mutant APP that lacks a mitochondrial localization signal, inhibits lipid stress–mediated hyperactive mitophagy in aging T cells, improving their antitumor functions. Growth of melanoma xenograft or carcinogen-induced oral cancer models was highly reduced in AD mice. Additionally, adoptive cell transfer–based immunotherapy using aging T cells isolated from AD mice suppressed tumor growth. The metabolic signature of stress-dependent mitophagy in T cells showed fumarate depletion, which was linked to decreased succination of Parkin and enhanced mitochondrial damage. Mechanistically, APP interaction with the TOMM complex at the outer mitochondrial membrane attenuated trafficking of ceramide synthase CerS6 to mitochondria in aging AD T cells, preventing ceramide-dependent mitophagy. Thus, APP restored mitochondrial fumarate metabolism and Parkin succination, improving antitumor functions of AD T cells in vitro and in vivo . Exogenous fumarate supplementation or healthy AD mitochondria transfer functionally mimicked the AD/APP phenotype in aging T cells, enhancing their antitumor activity to control tumor growth. Moreover, T cells isolated from aging donors showed elevated mitophagy with fumarate depletion, which was restored in T cells isolated from age-matched patients with AD. Together, these findings show that AD protects T cells against ceramide-dependent mitophagy and fumarate depletion to enhance antitumor functions. Significance: The reduced cancer risk in Alzheimer's disease patients is mediated by the amyloid-β 40 peptide, which inhibits aging-dependent mitophagy in T cells to improve antitumor immunity. See related commentary by Bieberich, p. 3579
Year:
2025
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2023
Collaborators (11)
Besim Ogretmen
Professor
Medical University of South Carolina
Kumar Sambamurti
Professor
Medical University of South Carolina
Özgür Şahin
Professor and SmartState Endowed Chair
Medical University of South Carolina
Natalia Oleinik
Res. Assistant Professor
Medical University of South Carolina
Breege Howley
Research Assistant Professor
Medical University of South Carolina
Onder Albayram
Assistant Professor
Medical University of South Carolina
Bidyut Mohanty
Associate Professor
Edward Via College of Osteopathic Medicine
Shikhar Mehrotra
Medical University of South Carolina
Kalyani Sonawane
Assistant Director of Data and Analytics
University of Texas School of Public Health
Ashish Deshmukh
Professor
Medical University of South Carolina
Annamarie Dalton
Assistant Professor
Medical University of South Carolina
Make your next move.
Prepare your application
Review drafts before you send them.